Across TCGA pan-cancer cohorts, OR5B17 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated OR5B17 data layer compared with 8 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher OR5B17 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR5B17 expression acts as an unfavorable survival marker.

LUSC, LIHC, and UCEC are the cancer types where OR5B17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	III,IV	0.500	0.664	<.001	16	view →
LIHC	OS	Median	All	0.031	0.775	<.001	8	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: OR5B17 tumor-vs-normal RNA expression · all OR5B17 data types